Business

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to

articleKorro Bio, Inc.February 27, 20235/company/frequency-therapeutics-inc/news/frequency-therapeutics-to-participate-at-upcoming-march-investor-conferences
Frequency Therapeutics to Participate at Upcoming March Investor Conferences

About this update from Korro Bio, Inc.

[{"type":"text","content":" LEXINGTON, Mass.--(BUSINESS WIRE)--\nFrequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences:\n\n43rd Annual Cowen Healthcare Conference: Dr. Loose will participate on a panel discussion on March 8th at 12:50 p.m. ET.\n\n33rd Annual Oppenheimer (Virtual) Healthcare Conference: Dr. Loose will provide a Company overview on Monday March 13th at 8:00 a.m. ET.\n\nLive conference webcasts can be accessed on the Investors and Media section of the Company’s website, investors.frequencytx.com. A replay will be posted following each event.\n\nAbout Frequency Therapeutics\n\nHeadquartered in Lexington, Mass., Frequency Therapeutics is pioneering a new category in regenerative medicine that aims to restore human function by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells. The Company’s lead preclinical program is designed to activate oligodendrocyte precursor cells with the goal of driving remyelination and potential functional recovery for individuals living with multiple sclerosis. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230227005295/en/\n\nInvestors:\nCarlo Tanzi, Ph.D.\nKendall Investor Relations\[email protected]\n617-914-0008\n\nMedia:\nFrequency Therapeutics\nEmail: [email protected]\n\nSource: Frequency Therapeutics, Inc.","length":3639,"tagName":"div"}]

More updates from Korro Bio, Inc.